Background Despite anticoagulation, patients with atrial fibrillation (AF) experience persistent elevated cardiovascular risk ...
Abbott has announced the company has received approval from the U.S. Food and Drug Administration (FDA) for its Volt PFA ...
Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...
Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.
US FDA approves Abbott's Volt PFA System to treat patients with atrial fibrillation: Abbott Park, Illinois Wednesday, December 24, 2025, 12:00 Hrs [IST] Abbott, is a global health ...
ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.
As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more ...
Zacks Investment Research on MSN
Should you hold on to BSX stock despite its premium valuation?
Boston Scientific BSX has a stretched valuation, reflected in its Value Score of C. Shares of the company are trading at a forward five-year price/earnings (P/E) of 27.77X, above its median as well as ...
The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for ...
Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...
The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...
Abbott can now compete with Medtronic, Boston Scientific and J&J in the U.S. for the fast-growing pulsed field ablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback